An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Pharmacodynamics
- Acronyms PhilosoPhi34; REL-PhilosoPhi34 study
- 11 Jan 2021 Status changed from active, no longer recruiting to completed.
- 08 Sep 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 08 Sep 2020 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2020.